Suggestions
Maryna Kolochavina
Rare and Orphan│Ultra-rare│Pediatrics│Advanced Therapy│Combined Medicinal Products│Omics│ Asset Integrated Lifecycle Management│Asset & Franchise Strategy│Asset & Portfolio Transactions│Patient’s Ecosystem
Maryna Kolochavina, PharmD, PMP, is an accomplished executive leader and trusted advisor with extensive expertise in lifecycle asset management, particularly in rare and orphan medicinal products. She currently serves as the Executive Director at Syneos One, a division of Syneos Health. Maryna has over 16 years of experience managing the lifecycle of more than 170 rare and orphan medicinal products, including advanced therapies such as ATMPs and stem cell treatments.124
Her professional background includes planning and executing various study designs across multiple phases (pre-clinical to Phase IV), including observational registries, safety surveillance studies, non-interventional studies, and compassionate use programs. She is also actively involved in patient advocacy for rare and orphan conditions through initiatives like the Patient Voice program at Charité in Berlin, Germany.234
Maryna holds a PharmD in clinical pharmacology from the National Medical Academy in Gdansk, Poland, and has certifications from organizations such as ACRP, BARQA, ASQ, and PMI. She is recognized for her innovative contributions to integrated development plans aimed at accelerating drug approval processes and strengthening asset value for rare diseases.24
